Target Information

Target General Infomation
Target ID
T28076
Former ID
TTDI01961
Target Name
Fibroblast growth factor-4
Gene Name
FGF4
Synonyms
Fibroblast growth factor 4; HBGF4; HST; HST1; HSTF1; Heparin secretorytransforming protein 1; Heparinbinding growth factor 4; Transforming protein KS3; FGF4
Target Type
Successful
Disease Angina pectoris [ICD9: 413; ICD10: I20]
Heart disease [ICD9: 390-429; ICD10: I00-I52]
Interstitial cystitis; Painful bladder syndrome [ICD9: 595.1,338,780; ICD10: N30.1, G89, R52]
Function
Plays an important role in the regulation of embryonic development, cell proliferation, and cell differentiation. Required for normal limb and cardiac valve development during embryogenesis.
BioChemical Class
Heparin-binding growth factors family
UniProt ID
P08620
Sequence
MSGPGTAAVALLPAVLLALLAPWAGRGGAAAPTAPNGTLEAELERRWESLVALSLARLPV
AAQPKEAAVQSGAGDYLLGIKRLRRLYCNVGIGFHLQALPDGRIGGAHADTRDSLLELSP
VERGVVSIFGVASRFFVAMSSKGKLYGSPFFTDECTFKEILLPNNYNAYESYKYPGMFIA
LSKNGKTKKGNRVSPTMKVTHFLPRL
Drugs and Mode of Action
Drug(s) Pentosan Polysulfate Drug Info Approved Interstitial cystitis; Painful bladder syndrome [538539]
Ad5FGF-4 Drug Info Phase 3 Angina pectoris [523829]
Alferminogene tadenovec Drug Info Phase 3 Heart disease [529400]
Modulator Ad5FGF-4 Drug Info [526882]
Alferminogene tadenovec Drug Info [529400]
Pentosan Polysulfate Drug Info [556264]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway MAPK signaling pathway
Ras signaling pathway
Rap1 signaling pathway
PI3K-Akt signaling pathway
Regulation of actin cytoskeleton
Pathways in cancer
Melanoma
PANTHER Pathway FGF signaling pathway
Pathway Interaction Database Regulation of nuclear beta catenin signaling and target gene transcription
FGF signaling pathway
Reactome PI3K Cascade
PIP3 activates AKT signaling
FGFR4 ligand binding and activation
FGFR3c ligand binding and activation
FGFR2c ligand binding and activation
FGFR3 mutant receptor activation
Activated point mutants of FGFR2
Constitutive Signaling by Aberrant PI3K in Cancer
FGFR1
Phospholipase C-mediated cascade
Phospholipase C-mediated cascade
Phospholipase C-mediated cascade
FGFR1
FGFR1
FRS-mediated FGFR1 signaling
FGFR2
FGFR2
FRS-mediated FGFR2 signaling
FGFR3
FRS-mediated FGFR3 signaling
FGFR3
FRS-mediated FGFR4 signaling
FGFR4
FGFR4
Negative regulation of FGFR1 signaling
Negative regulation of FGFR2 signaling
Negative regulation of FGFR3 signaling
Negative regulation of FGFR4 signaling
RAF/MAP kinase cascade
WikiPathways Regulation of Actin Cytoskeleton
MAPK Signaling Pathway
Differentiation Pathway
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
PIP3 activates AKT signaling
Signaling by FGFR
References
Ref 523829ClinicalTrials.gov (NCT01550614) Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease. U.S. National Institutes of Health.
Ref 529400Alferminogene tadenovec, an angiogenic FGF4 gene therapy for coronary artery disease. IDrugs. 2008 Apr;11(4):283-93.
Ref 538539FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020193.
Ref 526882Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease. Am J Cardiol. 2003 Nov 7;92(9B):24N-31N.
Ref 529400Alferminogene tadenovec, an angiogenic FGF4 gene therapy for coronary artery disease. IDrugs. 2008 Apr;11(4):283-93.
Ref 556264Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.